Chagin Karen Deborah 4
4 · Context Therapeutics Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Context Therapeutics CMO Karen Chagin Receives 290,000-Share Option Award
What Happened Karen Deborah Chagin, Chief Medical Officer of Context Therapeutics (CNTX), was granted a derivative award covering 290,000 shares on February 19, 2026. The filing reports an acquisition price of $0.00 (derivative instrument) — this was a grant of an option/award, not an open-market purchase or sale, so no cash changed hands and no shares were sold.
Key Details
- Transaction date: 2026-02-19; Form 4 filed: 2026-02-23 (timely filing).
- Instrument/amount: Grant/award (derivative) for 290,000 shares; acquisition price reported as $0.00.
- Vesting: 25% vests on Feb 19, 2027; remaining 75% vests in equal monthly installments over the next three years, subject to continued service (per footnote F1).
- Shares owned after transaction: not specified in the provided summary of the filing.
- No 10b5-1 plan, tax withholding, or cashless exercise reported in the provided information.
Context This was an equity award (option/derivative) with a multi-year vesting schedule — common for employee retention and long-term incentive plans. Because it’s a grant (not a purchase or sale), it doesn’t directly signal buying/selling intent and does not provide immediate liquidity. Monitor future Form 4s if/when options vest and are exercised or if any shares are sold.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-02-19+290,000→ 290,000 totalExercise: $2.32Exp: 2036-02-18→ Common Stock (290,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.